Skip to main content

11 Result(s)

within U Steidl Remove this filter

and

  1. No Access

    Article

    High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort

    S Goel, J Hall, K Pradhan, C Hirsch, B Przychodzen, A Shastri, I Mantzaris… in Leukemia (2016)

  2. No Access

    Article

    Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies

    Thrombocytopenia is commonly seen in myelodysplastic syndrome (MDS) patients, and bleeding complications are a major cause of morbidity and mortality. Thrombocytopenia is an independent factor for decreased su...

    W Li, K Morrone, S Kambhampati, B Will, U Steidl, A Verma in Leukemia (2016)

  3. No Access

    Article

    Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes

    Myelodysplastic syndromes (MDSs) are a group of heterogeneous clonal hematologic malignancies that are characterized by defective bone marrow (BM) hematopoiesis and by the occurrence of intramedullary apoptosi...

    I Gañán-Gómez, Y Wei, D T Starczynowski, S Colla, H Yang, M Cabrero-Calvo… in Leukemia (2015)

  4. No Access

    Article

    Stem cell origin of myelodysplastic syndromes

    Myelodysplastic syndromes (MDS) are common hematologic disorders that are characterized by decreased blood counts due to ineffective hematopoiesis. MDS is considered a ‘preleukemic’ disorder linked to a signif...

    H K Elias, C Schinke, S Bhattacharyya, B Will, A Verma, U Steidl in Oncogene (2014)

  5. No Access

    Article

    Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice

    PU.1 downregulation within hematopoietic stem and progenitor cells (HSPCs) is the primary mechanism for the development of acute myeloid leukemia (AML) in mice with homozygous deletion of the upstream regulato...

    P Basova, V Pospisil, F Savvulidi, P Burda, K Vargova, L Stanek, M Dluhosova… in Oncogene (2014)

  6. No Access

    Article

    The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells

    In this report, the effects of a combined treatment with the proteasome inhibitor bortezomib and either a recombinant adeno-associated virus type 2 (rAAV-2)-mediated p53 gene transfer or chemotherapeutic agent...

    J Neukirchen, A Meier, A Rohrbeck, G Garcia-Pardillos, U Steidl… in Cancer Gene Therapy (2007)

  7. No Access

    Article

    Cyclosporine A and Mycophenolate Mofetil vs Cyclosporine A and Methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings

    The combination of Cyclosporin A (CSA) and Methotrexate (MTX) is considered to be the standard regimen for the prevention of graft-versus-host disease (GVHD) after stem cell transplantation (SCT) from HLA-iden...

    F Neumann, T Graef, C Tapprich, M Vaupel, U Steidl… in Bone Marrow Transplantation (2005)

  8. No Access

    Article

    Gene expression profiling of Philadelphia chromosome (Ph)-negative CD34+ hematopoietic stem and progenitor cells of patients with Ph-positive CML in major molecular remission during therapy with imatinib

    F Neumann, N Teutsch, S Kliszewski, S Bork, U Steidl, B Brors, N Schimkus… in Leukemia (2005)

  9. No Access

    Article

    Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma

    Following induction therapy and 4 g/m2 cyclophosphamide, a single dose of 12 mg polyethyleneglycol-conjugated G-CSF (pegfilgrastim; n=12) or daily doses of unconjugated G-CSF (8.5 μg/kg/day) (n=12) were administe...

    U Steidl, R Fenk, I Bruns, F Neumann, M Kondakci, B Hoyer… in Bone Marrow Transplantation (2005)

  10. No Access

    Article

    Single-agent thalidomide for treatment of first relapse following high-dose chemotherapy in patients with multiple myeloma

    R Fenk, B Hoyer, U Steidl, M Kondakci, T Graef, R Heuk, L Ruf, C Strupp… in Leukemia (2005)

  11. No Access

    Article

    Intercellular adhesion molecule 1 on monocytes mediates adhesion as well as trans-endothelial migration and can be downregulated using antisense oligonucleotides

    The intercellular adhesion molecule 1 (ICAM-1) on endothelial cells is involved in the recruitment of leukocytes to inflammatory sites. In contrast to ICAM-1 expression on endothelial cells, little is known a...

    U. Steidl, R. Haas, R. Kronenwett in Annals of Hematology (2000)